Novo Nordisk: Investors Focusing On CagriSema Results Are Missing The Big Picture

2026-02-24 09:00:00 ET

Novo Nordisk A/S ( NVO ), listed in its home market as NOVO-B.CO, brought out a press release on February 23rd concerning results from its latest phase 3 trial for CagriSema. This is the company’s next-generation injectable weight loss drug, which combines semaglutide (Wegovy) with a new compound called cagrilintide. The results of the trial, which compared the Cagri/Sema combo with tirzepatide (Zepbound), did not reach its primary endpoint, which was to prove that CagriSema was "non-inferior" to its rival. The data showed that CagriSema helped patients lose 23% of their body weight after 84 weeks, while tirzepatide helped patients lose 25.5%....

Read the full article on Seeking Alpha

For further details see: